Home › Research › Treatments
Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan
Nakamura K, Sekijima Y.. Journal of human genetics, 2026-11-04
Topic: Risk, prevention and care in population studies
Plain-language summary
Recent advances in hereditary dementia research have clarified its molecular pathogenesis and clinical applications, with several advances already reaching implementation. The late 2023 introduction of anti-amyloid β therapies for Alzheimer's disease (AD) in Japan marked the beginning of a transformative era, though amyloid-related imaging abnormalities (ARIA) remain a notable adverse effect. Because APOE genotype, and ε4 dose in particular, is a major determinant of ARIA, genotyping is now embedded in pretreatment assessment. This review examines how one national health system has incorporated these advances and distinguishes between two frequently conflated domains: real-world clinical practice and clinical research. Practically, we describe the Guidelines for the Appropriate Use of APOE Genetic Testing in Dementia, established in 2025 and revised in 2026 following national health insurance approval, which position APOE testing as a pharmacogenetic tool governing monitoring intensity rather than treatment eligibility. We consider what the lower ε4 allele frequency in Japan implies, now that per-genotype effect estimates have been revised to values comparable to those in European-ancestry populations, and we set out the counseling required when a pharmacogenetic result carries risk information for untested relatives. On the research side, we describe the Hereditary Dementia Trial Ready Cohort, a national registry spanning 21 causative genes, and explain why its scope diverges from that of autosomal dominant AD-focused international initiatives such as DIAN. We conclude that features of the Japanese experience are most likely to be transferred to other healthcare systems.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nakamura, K., & Sekijima, Y. (2026). Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan. Journal of human genetics. https://doi.org/10.1038/s10038-026-01526-2
Vancouver
Nakamura K, Sekijima Y. Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan. Journal of human genetics. 2026. doi:10.1038/s10038-026-01526-2. PMID: 42982982.
BibTeX
@article{nakamura2026-42982982,
author = {Nakamura, K. and Sekijima, Y.},
title = {{Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan}},
journal = {Journal of human genetics},
year = {2026},
doi = {10.1038/s10038-026-01526-2},
pmid = {42982982},
url = {https://doi.org/10.1038/s10038-026-01526-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We consider what the lower ε4 allele frequency in Japan implies, now that per-genotype effect estimates have been revised to values comparable to those in European-ancestry populations, and we set out the counseling required when a pharmacogenetic result carries risk information for untested relatives.
- We conclude that features of the Japanese experience are most likely to be transferred to other healthcare systems.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthModerate
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 58 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of human genetics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42982982) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 58 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “counseling”
2 studies in the library carry the topic tag “counseling”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.